Share

February 05, 2013; 80 (6) Clinical/Scientific Notes

Cerebellar ataxia with SYNE1 mutation accompanying motor neuron disease

Yuishin Izumi, Ryosuke Miyamoto, Hiroyuki Morino, Akio Yoshizawa, Kazuto Nishinaka, Fukashi Udaka, Masakuni Kameyama, Hirofumi Maruyama, Hideshi Kawakami
First published January 16, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182815529
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
354

Share

This article has a correction. Please see:

Article Information

vol. 80 no. 6 600-601
DOI: 
https://doi.org/10.1212/WNL.0b013e3182815529
PubMed: 
23325900
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received July 12, 2012
  • Accepted September 21, 2012
  • First Published January 16, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Yuishin Izumi, MD, PhD,
    2. Ryosuke Miyamoto, MD,
    3. Hiroyuki Morino, MD, PhD,
    4. Akio Yoshizawa, PhD,
    5. Kazuto Nishinaka, MD,
    6. Fukashi Udaka, MD, PhD,
    7. Masakuni Kameyama, MD, PhD,
    8. Hirofumi Maruyama, MD, PhD and
    9. Hideshi Kawakami, MD, PhD
  1. Yuishin Izumi, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ryosuke Miyamoto, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Hiroyuki Morino, MD, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Akio Yoshizawa, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Kazuto Nishinaka, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Fukashi Udaka, MD, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Masakuni Kameyama, MD, PhD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Hirofumi Maruyama, MD, PhD and
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. American Journal of Neurodegenerative Disease, Associate Editorial Board, 2012

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Cabinet Office, Government of Japan/Funding Program for Next Generation World-Leading Researchers, LS088, representative, 2011-2012

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Hideshi Kawakami, MD, PhD
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Funded as the primary investigator by Grant-in-Aid for Scientific Research on Innovative Areas(Grant Number 23111008)(2011-Present),and the primary investigator by Grant-in-Aid for Exploratory Research(Grant Number 23659456)(2011-Present) by The Ministry of Education,Culture,Sports,Science and Technology Japan Grant-in-Aid for Exploratory Research

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (Y.I., K.N., F.U., M.K.), Sumitomo Hospital, Osaka; Department of Neurology (Y.I., R.M.), Tokushima University Hospital, Tokushima; and Department of Epidemiology (R.M., H. Morino, A.Y., H. Maruyama, H.K.), Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  1. Correspondence to Dr. Maruyama: hmaru{at}hiroshima-u.ac.jp
View Full Text

Article usage

Article usage: January 2013 to April 2022

AbstractFullPdfSource
Jan 20130133Highwire
Feb 201303159Highwire
Mar 2013089Highwire
Apr 201301113Highwire
May 2013063Highwire
Jun 201332137Highwire
Jul 201340119Highwire
Aug 20131996Highwire
Sep 20132052Highwire
Oct 20132775Highwire
Nov 20132188Highwire
Dec 201314101Highwire
Jan 20141064Highwire
Feb 201414108Highwire
Mar 20141921Highwire
Apr 20141964Highwire
May 2014743Highwire
Jun 2014641Highwire
Jul 20143353Highwire
Aug 20143022Highwire
Sep 20141411Highwire
Oct 20141323Highwire
Nov 20141666Highwire
Dec 20141265Highwire
Jan 201513107Highwire
Feb 2015733Highwire
Mar 20151274Highwire
Apr 20151451Highwire
May 20151782Highwire
Jun 20151510Highwire
Jul 20153977Highwire
Aug 20151611Highwire
Sep 20151554Highwire
Oct 20151422Highwire
Nov 20151722Highwire
Dec 20151452Highwire
Jan 20161951Highwire
Feb 20162134Highwire
Mar 20162123Highwire
Apr 20161243Highwire
May 20162197Highwire
Jun 20161321Highwire
Jul 20161320Highwire
Aug 20161763Highwire
Sep 20161332Highwire
Oct 20161622Highwire
Nov 20161924Highwire
Dec 20161011Highwire
Jan 20171921Highwire
Feb 2017841Highwire
Mar 20171141Highwire
Apr 20171213Highwire
May 20172122Highwire
Jun 20172051Highwire
Jul 2017511Highwire
Aug 20171000Highwire
Sep 20171500Highwire
Oct 20171783Highwire
Nov 20171166Highwire
Dec 20172500Highwire
Jan 20182423Highwire
Feb 20182730Highwire
Mar 20183811Highwire
Apr 20182753Highwire
May 20184200Highwire
Jun 20183353Highwire
Jul 20181332Highwire
Aug 20184842Highwire
Sep 20181522Highwire
Oct 20184812Highwire
Nov 20183722Highwire
Dec 20183502Highwire
Jan 20192301Highwire
Feb 20192200Highwire
Mar 20193021Highwire
Apr 20193635Highwire
May 20192322Highwire
Jun 20192432Highwire
Jul 20191711Highwire
Aug 20192212Highwire
Sep 20191411Highwire
Oct 20193901Highwire
Nov 20194710Highwire
Dec 20192201Highwire
Jan 20202200Highwire
Feb 20203200Highwire
Mar 20202001Highwire
Apr 20201300Highwire
May 20201901Highwire
Jun 20203022Highwire
Jul 20201133Highwire
Aug 20203622Highwire
Sep 20205110Highwire
Oct 20204303Highwire
Nov 20203620Highwire
Dec 20204212Highwire
Jan 20212011Highwire
Feb 20213512Highwire
Mar 20214201Highwire
Apr 20212211Highwire
May 20213943Highwire
Jun 20212912Highwire
Jul 20214710Highwire
Aug 20213631Highwire
Sep 20213132Highwire
Oct 20215720Highwire
Nov 20216012Highwire
Dec 20214853Highwire
Jan 20223620Highwire
Feb 20224121Highwire
Mar 20225611Highwire
Apr 20223210Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me